OA11380A - Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists. - Google Patents

Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists. Download PDF

Info

Publication number
OA11380A
OA11380A OA1200000138A OA1200000138A OA11380A OA 11380 A OA11380 A OA 11380A OA 1200000138 A OA1200000138 A OA 1200000138A OA 1200000138 A OA1200000138 A OA 1200000138A OA 11380 A OA11380 A OA 11380A
Authority
OA
OAPI
Prior art keywords
methoxy
methyl
dihydroisobenzofuran
trifluoromethyl
alkyl
Prior art date
Application number
OA1200000138A
Other languages
English (en)
Inventor
Kunio Satake
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11380A publication Critical patent/OA11380A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200000138A 1997-11-19 2000-05-12 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists. OA11380A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9701466 1997-11-19

Publications (1)

Publication Number Publication Date
OA11380A true OA11380A (en) 2004-01-27

Family

ID=11004634

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000138A OA11380A (en) 1997-11-19 2000-05-12 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists.

Country Status (40)

Country Link
US (2) US20030208079A1 (fr)
EP (1) EP1032571B1 (fr)
JP (2) JP3394239B2 (fr)
KR (1) KR100366902B1 (fr)
CN (1) CN1173974C (fr)
AP (1) AP909A (fr)
AR (1) AR016422A1 (fr)
AT (1) ATE219078T1 (fr)
AU (1) AU734218B2 (fr)
BG (1) BG63969B1 (fr)
CA (1) CA2310627C (fr)
CO (1) CO4771153A1 (fr)
CZ (1) CZ297315B6 (fr)
DE (1) DE69806045T2 (fr)
DK (1) DK1032571T3 (fr)
DZ (1) DZ2655A1 (fr)
EA (1) EA002621B1 (fr)
ES (1) ES2177058T3 (fr)
HK (1) HK1033313A1 (fr)
HR (1) HRP20000313B1 (fr)
HU (1) HUP0101112A3 (fr)
ID (1) ID24240A (fr)
IL (1) IL135631A0 (fr)
IS (1) IS2202B (fr)
MA (1) MA26567A1 (fr)
MY (1) MY120558A (fr)
NO (2) NO20002544L (fr)
NZ (1) NZ503912A (fr)
OA (1) OA11380A (fr)
PA (1) PA8463001A1 (fr)
PE (1) PE20000021A1 (fr)
PL (1) PL193484B1 (fr)
PT (1) PT1032571E (fr)
RS (1) RS49792B (fr)
SK (1) SK283460B6 (fr)
TN (1) TNSN98210A1 (fr)
TR (1) TR200001463T2 (fr)
TW (1) TW426667B (fr)
UA (1) UA59417C2 (fr)
WO (1) WO1999025714A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
OA11864A (en) * 1999-05-06 2006-03-03 Pfizer Prod Inc Substituted benzolactam compounds.
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
KR100453301B1 (ko) * 1999-05-21 2004-10-20 화이자 프로덕츠 인크. 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체
AU7557000A (en) * 1999-10-07 2001-05-10 Hisamitsu Pharmaceutical Co. Inc. Piperidine derivatives
ES2211455T3 (es) * 1999-10-18 2004-07-16 Pfizer Products Inc. Procedimiento para la preparacion de compuestos eteres ciclicos piperidinilaminometil trifluorometilicos.
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
DE60213043T2 (de) 2001-08-30 2007-01-04 Pfizer Products Inc., Groton Verfahren zur Herstellung von 2-(4-Alkyl-1-Piperazinyl)-Benzaldehyd und -Benzylidenyl-Derivaten durch Nucleophile Substitution von 2-Fluorobenzaldehyd mit 4-Alkyl-1-Piperazinen in Wasser als Lösungsmittel
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
CA2496447A1 (fr) * 2002-08-27 2004-03-11 Mark L. Witten Amelioration des effets de la fumee de cigarette
US6911544B2 (en) * 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102008000891A1 (de) 2008-03-31 2009-10-01 Robert Bosch Gmbh Schutzsystem für Werkzeugmaschinen
WO2013004766A1 (fr) 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
AU2019223237A1 (en) 2018-02-26 2020-09-03 Ospedale San Raffaele S.R.L. NK-1 antagonists for use in the treatment of ocular pain
EP4117673A1 (fr) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Traitement d'une déficience en cellules souches

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
DE69617226T2 (de) * 1995-03-27 2002-07-25 Hisamitsu Pharmaceutical Co Piperidinderivate.
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
ATE199552T1 (de) * 1995-07-07 2001-03-15 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6329396B1 (en) * 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
KR100453301B1 (ko) * 1999-05-21 2004-10-20 화이자 프로덕츠 인크. 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체
ES2211455T3 (es) * 1999-10-18 2004-07-16 Pfizer Products Inc. Procedimiento para la preparacion de compuestos eteres ciclicos piperidinilaminometil trifluorometilicos.

Also Published As

Publication number Publication date
TR200001463T2 (tr) 2000-12-21
AR016422A1 (es) 2001-07-04
DE69806045D1 (en) 2002-07-18
JP3394239B2 (ja) 2003-04-07
PE20000021A1 (es) 2000-02-25
US20050171354A1 (en) 2005-08-04
WO1999025714A1 (fr) 1999-05-27
AU734218B2 (en) 2001-06-07
NO20002544L (no) 2000-07-17
AU9454998A (en) 1999-06-07
DE69806045T2 (de) 2002-11-14
BG63969B1 (bg) 2003-08-29
CO4771153A1 (es) 1999-04-30
BG104437A (en) 2001-02-28
RS49792B (sr) 2008-06-05
JP2003040777A (ja) 2003-02-13
HUP0101112A3 (en) 2002-06-28
KR100366902B1 (ko) 2003-01-09
PL193484B1 (pl) 2007-02-28
CZ20001834A3 (cs) 2001-07-11
EA002621B1 (ru) 2002-06-27
TW426667B (en) 2001-03-21
AP9801402A0 (en) 1998-12-31
NO20042879L (no) 2000-07-17
IS2202B (is) 2007-02-15
ES2177058T3 (es) 2002-12-01
CA2310627C (fr) 2005-08-09
EP1032571B1 (fr) 2002-06-12
TNSN98210A1 (fr) 2005-03-15
SK283460B6 (sk) 2003-08-05
HRP20000313B1 (en) 2002-04-30
HUP0101112A2 (hu) 2002-05-29
PL340642A1 (en) 2001-02-12
AP909A (en) 2000-12-04
PA8463001A1 (es) 2000-09-29
CA2310627A1 (fr) 1999-05-27
HK1033313A1 (en) 2001-08-24
ATE219078T1 (de) 2002-06-15
SK7232000A3 (en) 2001-09-11
ID24240A (id) 2000-07-13
DZ2655A1 (fr) 2003-03-22
EA200000432A1 (ru) 2000-12-25
EP1032571A1 (fr) 2000-09-06
IL135631A0 (en) 2001-05-20
DK1032571T3 (da) 2002-07-15
JP2001523680A (ja) 2001-11-27
CN1279681A (zh) 2001-01-10
US20030208079A1 (en) 2003-11-06
YU29400A (sh) 2003-02-28
CN1173974C (zh) 2004-11-03
NO20002544D0 (no) 2000-05-18
HRP20000313A2 (en) 2000-12-31
IS5470A (is) 2000-04-26
UA59417C2 (uk) 2003-09-15
MY120558A (en) 2005-11-30
PT1032571E (pt) 2002-09-30
MA26567A1 (fr) 2004-12-20
NZ503912A (en) 2002-09-27
CZ297315B6 (cs) 2006-11-15

Similar Documents

Publication Publication Date Title
OA11380A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists.
CA2112129C (fr) Derive de l'oxazolidine et sel correspondant acceptable sur le plan pharmaceutique
HU202527B (en) Process for producing new quinuclidine derivatives and pharmaceutical compositions comprising same
US5721267A (en) Chemotherapeutic pyrrolocarbazole derivatives
Sauerberg et al. Cyclic carbamate analogs of pilocarpine
KR840001551B1 (ko) 시클로헥센 유도체의 제조방법
US8394824B2 (en) Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine
AU775861B2 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
US5210276A (en) Phenylethanolamino- and phenylethanolaminomethyl-tetralines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
JP2721631B2 (ja) アミノ安息香酸誘導体および中間体
US4837207A (en) Diastereoisomers of n6 -endo-bicyclo[2.2.1]heptyladenosine as antihypertensives with selective action
MXPA00004889A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists